BMS ties with Janssen on Factor XIa inhibitor programme
Bristol-Myers Squibb and Johnson & Johnson group Janssen have announced a deal to work together on a Factor XIa (FXIa) inhibitor programme.
Read More
Tag: thrombosis
GSK sells non-core assets to Aspen
GlaxoSmithKline is selling its portfolio of anaesthetics and thrombosis business to Aspen as it continues to simplify its business strategy through focusing on core therapeutic areas.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
